Soterix Medical Announces Clearance of SPRY Transcranial Magnetic Stimulation (TMS) Therapy for Major Depression
Soterix Medical Inc., the global leader in non-invasive stimulation and integrated brain monitoring technologies, announced clearance from the U.S. Food & Drug Administration (FDA) for the SPRY Transcranial Magnetic Stimulation (TMS) Therapy. SPRY TMS is indicated for the treatment of Major Depressive Disorder in adult patients, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.